| 货号 | MAB9591-SP |
| 别名 | EP; EPO; epoetin; erythropoietin; MGC138142; MVCD2 |
| 反应种属 | Mouse |
| 应用 | ELISA Capture (Matched Antibody Pair),ELISA Detection (Matched Antibody Pair),ELISA Standard ,Neutralization |
| 目标/特异性 | Detects mouse Erythropoietin in direct ELISAs. In direct ELISAs, approximately 25-50%cross-reactivity with recombinant rat Erythropoietin, 5-15% cross-reactivitywith recombinant human Erythropoietin, and no cross-reactivity with recombinantmouse Thrombopoietin is observed. |
| 使用方法 | ELISA Capture (Matched Antibody Pair): 2-8 µg/mL ELISA Detection (Matched Antibody Pair): 0.5-2.0 µg/mL ELISA Standard : Neutralization: Measured by its ability to neutralize Erythropoietin-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.15-0.75 µg/mL in the presence of 10 ng/mL Recombinant Mouse Erythropoietin. |
| 来源 | Monoclonal Rat IgG2A Clone # 148436 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 2056 (Human); 13856 (Mouse); 24335 (Rat) |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Chinese hamster ovary cell line CHO-derived recombinant mouse Erythropoietin Ala27-Arg192 Accession # P07321 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | Erythropoietin (Epo) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin (1). Its three N‑glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species (2, 3). Glycosylation of Epo is required for biological activities in vivo (4). Mature mouse Epo shares 95% amino acid sequence identity with rat Epo and 73%‑82% with bovine, canine, equine, feline, human, ovine, and porcine EPO. Epo is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules (5). It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain (6‑8). Epo promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the Epo receptor (Epo R) (8, 9). Epo R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells (7, 8, 10, 11). Ligand induced dimerization of Epo R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation (1, 12). Rapid regulation of circulating Epo allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce Epo production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha (1, 6). Epo additionally plays a tissue‑protective role in ischemia by blocking apoptosis and inducing angiogenesis (7, 8, 13). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Proliferation Induced by Erythropoietin and Neutralization by Mouse Erythropoietin Antibody. Recombinant Mouse Erythropoietin (Catalog # 959‑ME) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse Erythropoietin (10 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse Erythropoietin Monoclonal Antibody (Catalog # MAB9591). The ND50 is typically 0.15‑0.75 µg/mL. |
